Compare Novartis AG (NVS) vs Uber Technologies Inc (UBER) Price & Performance

Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.

The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.

Uber trades at $68.45, down 0.91% on the day, with a bearish technical signal despite strong fundamentals. The company reported $52.02B revenue in 2025 with $10.05B net income, maintaining robust growth from $44.0B revenue in 2024. Recent expansion includes the Costco delivery partnership reaching 47 states, while CEO Dara Khosrowshahi purchased $10 million in shares, signaling confidence.

Uber presents a compelling growth story with expanding profitability and dominant market position, though technical indicators suggest near-term pressure. The consensus price target of $104.72 implies 53% upside, supported by 82.5% analyst buy ratings. Key risks include robotaxi competition and projected negative cash flow in 2026.